A compelling first-mover investment at the intersection of Dubai's healthcare growth, the region's unmet oncology need, and world-first clinical technology.
Dubai's healthcare sector is growing at 8%+ annually. Cancer incidence across MENA is projected to increase 60% by 2035. British Oncology is positioned to capture this demand with first-mover technology advantage — including the first GammaPod in the entire Middle East, GCC and Africa.
First GammaPod in the Middle East, GCC and Africa. First adaptive LINAC cancer centre in Dubai Healthcare City. Technology advantage that will take competitors years to replicate.
2 billion+ people within 4 hours. Minimal domestic RT capacity across Africa and South Asia. Patients who currently travel to London or Frankfurt will travel to Dubai instead.
Clinical income (RT, PET-CT, consultations), insurance agreements, government contracts, medical tourism, clinical training and research partnerships.
"British Oncology" commands a significant brand premium in GCC and African healthcare markets, where British medical standards are synonymous with quality and trust.
Tax-free environment, DHA fast-track licensing, established patient flow ecosystem. DHCC is the GCC's premier healthcare free zone — ideal for medical tourism.
Phase 1: Dubai flagship. Phase 2: second LINAC to meet demand growth. Phase 3: regional expansion — Riyadh, Cairo, Lagos — under the British Oncology brand.
We share detailed financial projections, market analysis, technology specifications and our full business plan with qualified investors under NDA. Contact our investment team to begin the conversation.
Request Investor Pack